Candidalysin IgA

Serum candidalysin IgA is best read as a research-stage marker. It measures an IgA antibody in serum, the liquid part of blood. The published human diagnostic study measured serum IgG against candidalysin, not IgA, so the closest evidence is related but not identical.

That distinction matters because invasive candidiasis can be hard to confirm and dangerous when missed. A candidalysin antibody may add a clue when cultures or beta-glucan do not settle the question. It cannot diagnose invasive Candida infection by itself.

What Candidalysin Is

Candida albicans commonly lives on the skin, in the mouth, in the gut, and in the vagina without causing disease. When it grows into long filaments, the form tied to tissue invasion, it can release candidalysin.

Candidalysin is a small peptide toxin made from the ECE1 gene. In cell and animal studies, it damaged host-cell membranes and triggered immune alarms. That is the mechanistic reason antibodies against it are interesting: they may record exposure to a virulence factor, not just exposure to Candida as a harmless colonizer.

Candida albicans can cause mild mouth or vaginal infections, but it can also cause bloodstream and deep-organ disease in people with weak immune defenses, critical illness, central lines, broad antibiotic exposure, or major abdominal problems. This test is trying to point at the invasive side of that split. The evidence is still thin.

What This Test Measures

The test measures IgA aimed at candidalysin in serum. A higher result means more of that antibody was detected in blood. For an IgA version, what that means clinically has not been established.

The published pediatric diagnostic study measured serum anti-candidalysin IgG. IgG is a different antibody class. In that study, IgG helped separate children classified as invasive or probable invasive Candida cases from non-IC controls. It did not validate serum IgA.

Serum IgA is also different from secretory IgA. Secretory IgA is the antibody found on moist surfaces such as the gut, mouth, airways, and vagina. Studies of secretory IgA show it can bind Candida hyphae and candidalysin, but that is a local mucosal signal. A blood IgA test is not the same measurement.

The Human Evidence

The main human study used a serum anti-candidalysin IgG ELISA in children. It included 121 children with proven, probable, or possible invasive candidiasis and 105 non-IC controls. The validation work compared 20 proven cases with controls, then 77 proven or probable cases with controls.

The IgG test found about 80 of every 100 proven cases in one comparison and about 87 of every 100 proven or probable cases in the larger comparison. It also marked roughly 30 of every 100 non-IC controls positive. So even for IgG, this was an aid to diagnosis, not a verdict.

That is the gap to keep in mind. The IgG evidence is promising. The IgA version is exploratory until adult data, repeat testing data, and assay-specific cutoffs are published.

In adults, the most direct test of serum Candida antibodies is less encouraging. A secondary analysis of the CandiSep trial checked serum Candida IgA, IgM, and IgG assays in 342 ICU patients with sepsis and high invasive candidiasis risk. Antibody levels were not meaningfully higher in invasive infection, were confounded by simple colonization, and performed worse than antigen tests, catching fewer than 28 of every 100 invasive cases at a matched specificity. That adult data is a strong reason to treat a serum IgA approach cautiously.

Why It Can Disagree With Other Fungal Tests

In the IgG study, beta-glucan and anti-candidalysin IgG did not line up cleanly. When beta-glucan was positive, the antibody test was also positive about 89 times out of 100. When beta-glucan was negative, the two tests were both negative only about 16 times out of 100. These concordance numbers come from that single study and have not been replicated.

There are several possible reasons. Beta-glucan detects a fungal cell-wall sugar in blood. The candidalysin antibody detects your immune response to a toxin. These signals can appear at different times, and each assay has its own blind spots. A positive antibody with a negative beta-glucan is a reason to look at the whole picture, not proof that either test is wrong.

Why One Result Is Thin

There are no standard clinical cutoffs for serum candidalysin IgA. A single number should be held loosely, especially if symptoms, cultures, beta-glucan, blood counts, and risk factors do not point the same way.

A repeat result may help show whether the finding is reproducible or changing. But no study has shown how serum candidalysin IgA trends map to recovery, relapse, or treatment response. The trend is context, not proof.

When Results Can Mislead You

• Low antibody production: illness or immune-suppressing medication can blunt antibody responses, so a result can look falsely low during a real infection.
• Low or absent IgA: some people make very little IgA. A total IgA test checks whether an IgA-based result can be trusted.
• Colonization without invasion: Candida living harmlessly on the skin or mucosal surfaces can still drive an antibody response, so a positive result does not prove tissue-invading infection.
• Different Candida antibody panels: broad Candida antibody tests target many Candida antigens, not candidalysin alone. Results vary by assay and do not translate cleanly to this marker.
• Assay interference: antibody tests can be thrown off by cross-reacting substances or by very high antibody levels overwhelming the assay. These are lab problems, not biology you should act on.
• Local versus blood immunity: mucosal secretory IgA and serum IgA are different measurements. A blood result does not directly tell you what is happening on the gut, mouth, or vaginal surface.